Common Chemotherapy Cardiotoxicities 
 • Anthracyclines ...
239
Description

Common Chemotherapy Cardiotoxicities 

 • Anthracyclines (doxorubicin): HF, LV dysfunction (5-23% pts), based on cumulative dosage

 • HER2 agents (trastuzumab): 2.1% risk in reducing LV function, resolves once stopped, TTE q3mo

 • TKI (esp with sunitinib): HF, cardiac dysfunction

 • Angiogenesis inhibitors (bevacizumab, lenalidomide): HTN, 3-fold ↑ in arterial TE events

 • Platinum-based (cisplatin): HTN, HL, CAD, thromboembolic, in advanced testicular disease

 • Microtubule inhibitors (paclitaxel): arrhythmias

 • Anti-metabolites (5-FU, cytarabine): MI, angina, CP, EKG changes, 1-8% pts, early onset

 • Immune checkpoint inhibitor (ICI): fulminant lymphocytic myocarditis, HF, cardiac arrest; onset variable, risk factor = combo therapy

 • Radiation: CAD (up to 85%), pericardial dz (6-30%), CM (up to 10%), valvular abnl, PVD, arrhythmias, autonomic dysfunction, can occur 10-15 yrs later, many risk factors incl dosage, metabolic RF



#Cardiotoxicities #chemotherapy #diagnosis #pharmacology #SideEffects #AdverseEffects #Oncology
Contributed by

MGH White Book Manual
@MGHWhiteBook
Account created for the MGH Internal Medicine Housestaff Manual "White Book" - https://stk10.github.io/MGH-Docs/WhiteBook-2019-2020.pdf
0 Comments

Related content